Findings from a new study performed in mice suggest that omega-3 fatty acids could help immunotherapy and other treatments do a better job at fighting cancer. Immunotherapies, which stimulate the body’s own immune system to attack cancer, have revolutionized cancer treatment, but they don’t work for every patient.
For more than 20 years, Loyola Medicine has provided the Chicago area with allergy counts every weekday via Twitter during the allergy season. The Loyola Medicine Allergy Count will begin 2022 reporting on April 1.
Program employs a coordinated approach and serves as a template for response against rapidly evolving pandemic pathogens
Two new studies from the Global Virus Network (GVN) in partnership with the Petroleum Industry Health Organization of Iran provide evidence that getting the oral polio vaccine made from live, weakened poliovirus may protect people from COVID-19 infection by stimulating the immune system.
Johns Hopkins research shows that high-titer (antibody-rich) COVID convalescent plasma — when administered to COVID-19 outpatients within nine days after testing positive — reduced the need for hospitalization for more than half of a study’s predominantly unvaccinated outpatients.
With second boosters becoming available, schedules for first boosters recently changed, and new evidence about the protection offered by boosters in the Omicron surge, a guide for those who have not yet been boosted or are considering a second booster.
As we age, our immune system works less well. We become more susceptible to infections and vaccinations no longer work as effectively.
The ninth annual Harrington Prize for Innovation in Medicine has been jointly awarded to James E. Crowe, Jr., MD, Director, Vanderbilt Vaccine Center and Professor, Departments of Pediatrics and Pathology, Microbiology and Immunology, Vanderbilt School of Medicine, and Michel C. Nussenzweig, MD, PhD, Investigator, HHMI, and Zanvil A. Cohn and Ralph M. Steinman Professor, The Rockefeller University. The award recognizes their groundbreaking work, which has elucidated fundamental principles of the human immune response and enabled the use of human antibodies to treat COVID-19.
Pancreatic cancer is notoriously difficult to cure or even treat. Now, a new strategy devised by scientists at Albert Einstein College of Medicine has succeeded in making pancreatic tumors visible to the immune systems of mice and vulnerable to immune attack, reducing cancer metastases by 87%. The paper describing the findings published online today in Science Translational Medicine.
The U.S. Food and Drug Administration has approved a novel therapy for patients with metastatic or inoperable melanoma, an aggressive type of skin cancer. The treatment is developed based on original research conducted at the Johns Hopkins Kimmel Cancer Center.
People who consume sugar and other carbohydrates in excess over a long period of time have an increased risk of developing an autoimmune disease.
The new study suggests that children tend to have strong antibody responses after SARS-CoV-2 infection. Understanding antibody responses to SARS-CoV-2 at different ages can inform COVID-19 vaccine strategies and policies.
Ebola virus polymerase hijacks a cellular protein called GSPT1. An experimental drug that targets GSPT1 for degradation can also halt Ebola virus infection in human cells.
Fewer than 1 in 1,000 people who have been vaccinated or previously infected with COVID-19 were hospitalized with a new breakthrough infection, Mayo Clinic research finds. The study, which is published in Clinical Infectious Diseases, supports previous studies that show vaccination is the best way to prevent severe COVID-19 infection, hospitalization and death.
Our immune protection is provided by two systems working hand in hand. When infected with a virus, the immune system reacts by producing antibodies that can prevent the virus from infecting further cells.
Although allergies are widespread, their diagnosis is complex and, depending on the type of allergy, the prospects of success with therapy are not always clear.
Researchers at Texas Biomed and University of Alabama at Birmingham discovered an antibody cocktail against COVID-19 that appears effective against all variants and other coronaviruses. The cocktail has been exclusively licensed to Aridis Pharmaceuticals, which is seeking a manufacturing partner to advance the treatment to human clinical trials.
Children previously infected with COVID-19 develop natural circulating antibodies that last for at least seven months, according to a new study led by researchers at UTHealth Houston.
Replenishing the body’s high-density lipoprotein (HDL) could be an effective treatment for sepsis, according to a new University of Kentucky College of Medicine study published in Science Signaling. The lab study, led by Xiangan Li, Ph.D., a professor in the Department of Physiology and the Saha Cardiovascular Research Center, found that a synthetic form of HDL provided protection against sepsis in mice.
The team's latest study, published in Cell, shows that two clever human antibodies can target two ebolavirus species at once: Ebola virus and Sudan virus. These two species are responsible for the biggest, deadliest outbreaks. The new report suggests researchers could combine these two potent antibodies to make a powerful antiviral therapy.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
